International: +1-347-960-6455
Gram-Positive Bacterial Infections Therapeutics - Pipeline Analysis 2018

Gram-Positive Bacterial Infections Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10060 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Gram-positive bacterial infections are caused by gram-positive bacteria, such as Staphylococcus aureus and Enterococcus spp. This infection sometimes become fatal in the immune-compromised person, and it is generally found in new-born. The infection when contracted during pregnancy can cause chorioamnionitis and postpartum infections. Further, urinary tract infections associated with the bacteria can also cause premature birth. Some of the characteristics of gram-positive bacteria are thick peptidoglycan layer, presence of teichoic acids, DD-transpeptidase for cross-linking in the cell walls, and cytoplasmic lipid membrane. Gram-positive bacteria give positive result in gram stain test. Merck & Co. Inc. is in the process of developing tedizolid phosphate for the treatment of gram-positive bacterial infections. Pfizer Inc. is also involved in the pipeline for Gram-positive bacterial infections.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.